IL223163A0 - Monoclonal antibodies against her2 epitope - Google Patents

Monoclonal antibodies against her2 epitope

Info

Publication number
IL223163A0
IL223163A0 IL223163A IL22316312A IL223163A0 IL 223163 A0 IL223163 A0 IL 223163A0 IL 223163 A IL223163 A IL 223163A IL 22316312 A IL22316312 A IL 22316312A IL 223163 A0 IL223163 A0 IL 223163A0
Authority
IL
Israel
Prior art keywords
monoclonal antibodies
antibodies against
against her2
her2 epitope
epitope
Prior art date
Application number
IL223163A
Other languages
English (en)
Original Assignee
Genmab As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=44533416&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=IL223163(A0) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Genmab As filed Critical Genmab As
Publication of IL223163A0 publication Critical patent/IL223163A0/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77—Internalization into the cell
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Oncology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
IL223163A 2010-05-27 2012-11-20 Monoclonal antibodies against her2 epitope IL223163A0 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US34918210P 2010-05-27 2010-05-27
DKPA201000468 2010-05-27
PCT/EP2011/058772 WO2011147982A2 (en) 2010-05-27 2011-05-27 Monoclonal antibodies against her2 epitope

Publications (1)

Publication Number Publication Date
IL223163A0 true IL223163A0 (en) 2013-02-03

Family

ID=44533416

Family Applications (2)

Application Number Title Priority Date Filing Date
IL223163A IL223163A0 (en) 2010-05-27 2012-11-20 Monoclonal antibodies against her2 epitope
IL245274A IL245274B (en) 2010-05-27 2016-04-21 Monoclonal antibodies against the 2her epitope

Family Applications After (1)

Application Number Title Priority Date Filing Date
IL245274A IL245274B (en) 2010-05-27 2016-04-21 Monoclonal antibodies against the 2her epitope

Country Status (8)

Country Link
US (3) US9714294B2 (enExample)
EP (1) EP2575880B1 (enExample)
JP (2) JP6082344B2 (enExample)
CN (1) CN103153339B (enExample)
CA (1) CA2800769C (enExample)
IL (2) IL223163A0 (enExample)
NZ (1) NZ604007A (enExample)
WO (1) WO2011147982A2 (enExample)

Families Citing this family (60)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9272029B2 (en) 2009-03-26 2016-03-01 Ibc Pharmaceuticals, Inc. Interferon lambada-antibody complexes
CA3051311A1 (en) 2010-05-27 2011-12-01 Genmab A/S Monoclonal antibodies against her2
NZ604007A (en) * 2010-05-27 2015-03-27 Genmab As Monoclonal antibodies against her2 epitope
PL2635607T3 (pl) 2010-11-05 2020-05-18 Zymeworks Inc. Projekt stabilnego przeciwciała heterodimerowego z mutacjami w domenie FC
ES2676878T3 (es) 2011-03-03 2018-07-25 Zymeworks Inc. Diseño de armazón de heteromultímero multivalente y constructos
AU2012245116A1 (en) * 2011-04-20 2013-11-07 Genmab A/S Bispecific antibodies against HER2 and CD3
US20140161827A1 (en) * 2011-05-09 2014-06-12 University Of Virginia Patent Foundation Compositions and methods for treating cancer
UA117901C2 (uk) 2011-07-06 2018-10-25 Ґенмаб Б.В. Спосіб посилення ефекторної функції вихідного поліпептиду, його варіанти та їх застосування
PL2773671T3 (pl) 2011-11-04 2022-01-24 Zymeworks Inc. Projekt stabilnego przeciwciała heterodimerycznego z mutacjami w domenie fc
CN104159600B (zh) * 2012-01-26 2018-04-10 Ibc药品公司 用抗体靶向干扰素‑λ来有效增强抗肿瘤和抗病毒活性
CN104520327B (zh) * 2012-05-10 2019-01-18 酵活有限公司 单臂单价抗体构建体及其用途
US9499634B2 (en) 2012-06-25 2016-11-22 Zymeworks Inc. Process and methods for efficient manufacturing of highly pure asymmetric antibodies in mammalian cells
EP3632462A1 (en) 2012-07-06 2020-04-08 Genmab B.V. Dimeric protein with triple mutations
US11180572B2 (en) 2012-07-06 2021-11-23 Genmab B.V. Dimeric protein with triple mutations
AU2013289881B2 (en) 2012-07-13 2018-01-18 Zymeworks Bc Inc. Multivalent heteromultimer scaffold design and constructs
US9914785B2 (en) 2012-11-28 2018-03-13 Zymeworks Inc. Engineered immunoglobulin heavy chain-light chain pairs and uses thereof
MX385344B (es) 2012-11-28 2025-03-18 Zymeworks Bc Inc Pares de cadena pesada-cadena ligera de inmunoglobulina modificados genéticamente y usos de estos.
AU2013372331A1 (en) 2013-01-10 2015-07-23 Genmab B.V. Human IgG1 Fc region variants and uses thereof
CA2913363A1 (en) * 2013-05-24 2014-11-27 Zymeworks Inc. Modular protein drug conjugate therapeutic
US9738726B2 (en) 2013-06-11 2017-08-22 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services HER2-specific monoclonal antibodies and conjugates thereof
EP3072907B1 (en) 2013-11-19 2019-02-20 Remegen, Ltd Anti-her2 antibody and conjugate thereof
EP4570318A3 (en) 2013-11-27 2025-10-15 Zymeworks BC Inc. Bispecific antigen-binding constructs targeting her2
MX379030B (es) 2013-12-17 2025-03-10 Genentech Inc Anticuerpos anti-cd3 y metodos de uso
CA2925677A1 (en) 2013-12-20 2015-06-25 F. Hoffmann-La Roche Ag Bispecific her2 antibodies and methods of use
MX368396B (es) * 2014-01-10 2019-10-01 Synthon Biopharmaceuticals Bv Conjugados de anticuerpo-farmaco (adc) de duocarmicina que muestran actividad antitumoral in vivo mejorada.
JP6825909B2 (ja) 2014-02-28 2021-02-03 アラコス インコーポレイテッド シグレック−８関連疾患を処置するための方法および組成物
CN105017421B (zh) * 2014-04-16 2017-12-26 中国人民解放军海军总医院 一种抗her2双特异性抗体及其制备方法与应用
BR112016027888A2 (pt) 2014-05-28 2017-10-24 Zymeworks Inc construto de polipeptídeo de ligação ao antígeno isolado, polinucleotídeo isolado ou um conjunto de polinucleotídeos isolados, vetor ou conjunto de vetores, célula isolada, composição farmacêutica, uso do construto, método para tratar um sujeito com uma doença ou distúrbio, método para obter um construto, método para preparar um construto, meio de armazenamento legível por computador, método para produzir um construto de polipeptídeo de ligação com antígeno bi-específico e método para preparar um construto de polipeptídeo de ligação com antígeno isolado
TWI695011B (zh) 2014-06-18 2020-06-01 美商梅爾莎納醫療公司 抗ｈｅｒ２表位之單株抗體及其使用之方法
CN110642952B (zh) * 2014-08-14 2021-05-25 上海生物制品研究所有限责任公司 抗her3抗体、其制法及其应用
WO2016082044A1 (en) 2014-11-27 2016-06-02 Zymeworks Inc. Methods of using bispecific antigen-binding constructs targeting her2
CN105985435B (zh) 2015-01-30 2019-10-15 嘉和生物药业有限公司 全人源her2抗体的突变抗体及其编码基因和应用
CN104689335B (zh) * 2015-02-12 2017-12-01 中国科学院上海高等研究院 烯基磺酰胺基作为连接子的抗体药物偶联物及其应用
AU2016262168B2 (en) 2015-05-13 2022-06-23 Zymeworks Bc Inc. Antigen-binding constructs targeting HER2
CN107921127B (zh) * 2015-05-22 2022-04-08 纪念斯隆-凯特琳癌症中心 对于prame肽具有特异性的t细胞受体样抗体
HRP20231134T1 (hr) 2015-06-16 2024-01-05 F. Hoffmann - La Roche Ag Humanizirana i afinitetno zrela protutijela na fcrh5 i postupci za uporabu
CA2991799A1 (en) 2015-07-15 2017-01-19 Zymeworks Inc. Drug-conjugated bi-specific antigen-binding constructs
WO2017059551A1 (en) 2015-10-08 2017-04-13 Zymeworks Inc. Antigen-binding polypeptide constructs comprising kappa and lambda light chains and uses thereof
US10604577B2 (en) 2015-10-22 2020-03-31 Allakos Inc. Methods and compositions for treating systemic mastocytosis
ITUA20162242A1 (it) * 2016-04-01 2017-10-01 St Biochimico Italiano Giovanni Lorenzini Spa Un nuovo anticorpo anti-erbb2
EP3241847A1 (en) 2016-05-06 2017-11-08 MAB Discovery GmbH Her-2 binding antibodies
CN110505880A (zh) * 2016-11-04 2019-11-26 基因泰克公司 Her2阳性乳腺癌的治疗
KR20190074300A (ko) 2016-11-15 2019-06-27 제넨테크, 인크. 항-cd20/항-cd3 이중특이적 항체에 의한 치료를 위한 투약
CN108610419B (zh) * 2016-12-09 2020-08-18 泰州迈博太科药业有限公司 一种人源化抗her2单克隆抗体
CN110121505B (zh) 2016-12-28 2023-08-01 株式会社绿十字细胞治疗 嵌合抗原受体和表达其的自然杀伤细胞
JP7132232B2 (ja) * 2017-02-24 2022-09-06 マクロジェニクス，インコーポレーテッド Ｃｄ１３７及び腫瘍抗原に結合できる二重特異性結合分子並びにその使用
BR112019022912A2 (pt) 2017-05-05 2020-05-26 Allakos Inc. Métodos e composições para tratar doenças oculares alérgicas
PE20242042A1 (es) 2017-06-02 2024-10-10 Pfizer Anticuerpos especificos para flt3 y sus usos
US11517632B2 (en) * 2017-06-20 2022-12-06 Nanomab Technology Limited Anti-Her2 single chain antibody and coding sequence and use thereof
US11649294B2 (en) 2017-11-14 2023-05-16 GC Cell Corporation Anti-HER2 antibody or antigen-binding fragment thereof, and chimeric antigen receptor comprising same
EP3712178A4 (en) 2017-11-14 2021-08-11 Green Cross Lab Cell Corporation ANTI-HER2 ANTIBODIES OR ANTIGIBODY FRAGMENT THEREOF AND CHIMERAIR ANTIGEN RECEPTOR WITH IT
AR115360A1 (es) 2018-02-08 2021-01-13 Genentech Inc Moléculas de unión al antígeno y métodos de uso
SG11202007572VA (en) 2018-02-15 2020-09-29 Macrogenics Inc Variant cd3-binding domains and their use in combination therapies for the treatment of disease
CN108484772A (zh) * 2018-04-11 2018-09-04 中国人民解放军军事科学院军事医学研究院 抗her2抗原的人源化抗体h5l5及其应用
EP3810649A1 (en) 2018-06-22 2021-04-28 Genmab A/S Method for producing a controlled mixture of two or more different antibodies
CN110790840A (zh) * 2018-08-01 2020-02-14 三生国健药业（上海）股份有限公司 结合人her2的抗体、其制备方法和用途
KR102871791B1 (ko) 2018-09-10 2025-10-15 미라티 테라퓨틱스, 인크. 병용 요법
CA3137480A1 (en) * 2019-05-02 2020-11-05 Mab Discovery Gmbh Combination of her2 antibodies
KR20240007171A (ko) 2021-05-14 2024-01-16 제넨테크, 인크. 모수네투주맙 및 폴라투주맙 베도틴을 이용한 cd20 양성 증식성 장애의 치료 방법
WO2024183623A1 (zh) * 2023-03-03 2024-09-12 盛禾(中国)生物制药有限公司 一种抗her2抗体在制备治疗癌症的药物中的用途

Family Cites Families (111)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
JPS5896026A (ja) 1981-10-30 1983-06-07 Nippon Chemiphar Co Ltd 新規ウロキナ−ゼ誘導体およびその製造法ならびにそれを含有する血栓溶解剤
US4609546A (en) 1982-06-24 1986-09-02 Japan Chemical Research Co., Ltd. Long-acting composition
US4766106A (en) 1985-06-26 1988-08-23 Cetus Corporation Solubilization of proteins for pharmaceutical compositions using polymer conjugation
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
WO1989006692A1 (en) 1988-01-12 1989-07-27 Genentech, Inc. Method of treating tumor cells by inhibiting growth factor receptor function
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
US5703055A (en) 1989-03-21 1997-12-30 Wisconsin Alumni Research Foundation Generation of antibodies through lipid mediated DNA delivery
US5705157A (en) 1989-07-27 1998-01-06 The Trustees Of The University Of Pennsylvania Methods of treating cancerous cells with anti-receptor antibodies
US6884418B1 (en) 1989-08-04 2005-04-26 Berlex Laboratories, Inc. Use of ligand-mimicking agents and anti-neoplastic drugs in cancer therapy
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US5770429A (en) 1990-08-29 1998-06-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5874299A (en) 1990-08-29 1999-02-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5789650A (en) 1990-08-29 1998-08-04 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5814318A (en) 1990-08-29 1998-09-29 Genpharm International Inc. Transgenic non-human animals for producing heterologous antibodies
US6300129B1 (en) 1990-08-29 2001-10-09 Genpharm International Transgenic non-human animals for producing heterologous antibodies
AU8507191A (en) 1990-08-29 1992-03-30 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5877397A (en) 1990-08-29 1999-03-02 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
WO1992022645A1 (en) 1991-06-14 1992-12-23 Genpharm International, Inc. Transgenic immunodeficient non-human animals
JPH06508880A (ja) 1991-07-08 1994-10-06 ユニバーシティ　オブ　マサチューセッツ　アット　アムハースト サーモトロピック液晶セグメント化ブロックコポリマー
US5733743A (en) 1992-03-24 1998-03-31 Cambridge Antibody Technology Limited Methods for producing members of specific binding pairs
AU6819494A (en) 1993-04-26 1994-11-21 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US6077835A (en) 1994-03-23 2000-06-20 Case Western Reserve University Delivery of compacted nucleic acid to cells
US6410690B1 (en) 1995-06-07 2002-06-25 Medarex, Inc. Therapeutic compounds comprised of anti-Fc receptor antibodies
KR970029803A (ko) 1995-11-03 1997-06-26 김광호 반도체 메모리장치의 프리차지 회로
AU727082B2 (en) 1996-03-27 2000-11-30 Genentech Inc. ErbB3 antibodies
EP0931147A1 (en) 1996-10-18 1999-07-28 Genentech, Inc. ANTI-ErbB2 ANTIBODIES
ZA9811162B (en) 1997-12-12 2000-06-07 Genentech Inc Treatment with anti-ERBB2 antibodies.
US6417168B1 (en) 1998-03-04 2002-07-09 The Trustees Of The University Of Pennsylvania Compositions and methods of treating tumors
IL138034A0 (en) 1998-03-27 2001-10-31 Genentech Inc Apo-2 ligand-anti-her-2 antibody synergism
WO1999050392A1 (en) 1998-03-31 1999-10-07 Geron Corporation Methods and compositions for eliciting an immune response to a telomerase antigen
US7244826B1 (en) 1998-04-24 2007-07-17 The Regents Of The University Of California Internalizing ERB2 antibodies
CA2361421A1 (en) 1999-02-03 2000-08-10 Biosante Pharmaceuticals, Inc. Therapeutic calcium phosphate particles and methods of manufacture and use
WO2000069460A1 (en) 1999-05-14 2000-11-23 Genentech, Inc. TREATMENT WITH ANTI-ErbB2 ANTIBODIES
US6281005B1 (en) 1999-05-14 2001-08-28 Copernicus Therapeutics, Inc. Automated nucleic acid compaction device
JP4579471B2 (ja) 1999-06-25 2010-11-10 ジェネンテック， インコーポレイテッド 抗ＥｒｂＢ２抗体を用いる前立腺癌の処置
AT500848B1 (de) 1999-06-25 2008-01-15 Genentech Inc Humanisierte anti-erbb2-antikörper
US6949245B1 (en) 1999-06-25 2005-09-27 Genentech, Inc. Humanized anti-ErbB2 antibodies and treatment with anti-ErbB2 antibodies
BRPI0012196B8 (pt) 1999-06-25 2021-05-25 Genentech Inc artigo industrializado
DE60037896D1 (de) 1999-07-29 2008-03-13 Medarex Inc Menschliche antikörper gegen her2/neu
CN102766210B (zh) 1999-08-24 2015-07-08 E.R.施贵宝&圣斯有限责任公司 人ctla-4抗体及其应用
CN1447696A (zh) 2000-05-19 2003-10-08 杰南技术公司 用于提高对ErbB拮抗剂癌症治疗的有效应答可能性的基因检测试验
WO2002042468A2 (en) 2000-11-27 2002-05-30 Geron Corporation Glycosyltransferase vectors for treating cancer
IL155977A0 (en) 2000-11-30 2003-12-23 Medarex Inc Transgenic transchromosomal rodents for making human antibodies
EP1243276A1 (en) 2001-03-23 2002-09-25 Franciscus Marinus Hendrikus De Groot Elongated and multiple spacers containing activatible prodrugs
US7087600B2 (en) 2001-05-31 2006-08-08 Medarex, Inc. Peptidyl prodrugs and linkers and stabilizers useful therefor
WO2003062375A2 (en) 2001-12-19 2003-07-31 Genentech, Inc. Stabilizing polypeptides which have been exposed to urea
US7332585B2 (en) 2002-04-05 2008-02-19 The Regents Of The California University Bispecific single chain Fv antibody molecules and methods of use thereof
EP1510221A4 (en) 2002-06-03 2009-04-29 Mitsubishi Tanabe Pharma Corp MEANS FOR THE PREVENTION AND / OR TREATMENT OF PERSONS EXPRESSING OR ACTIVATING HER2 AND / OR EGFR
ES2533963T3 (es) 2002-10-10 2015-04-16 Merck Patent Gmbh Composiciones farmacéuticas dirigidas a receptores Erb-B1
US7705045B2 (en) 2002-11-14 2010-04-27 Syntarga, B.V. Prodrugs built as multiple self-elimination-release spacers
US7309486B1 (en) 2002-11-15 2007-12-18 Mark Zamoyski HER cancer protocols
WO2005034733A2 (en) 2003-10-08 2005-04-21 North Shore-Long Island Jewish Research Institute Methods and compositions for diagnosis and treatment of b cell chronic lymphocytic leukemia
AU2004309347B2 (en) 2003-12-19 2010-03-04 Genentech, Inc. Monovalent antibody fragments useful as therapeutics
MXPA06014075A (es) * 2004-06-03 2007-03-15 Novimmune Sa Anticuerpos anti-cd3 y metodos de uso de los mismos.
CN102532321B (zh) 2004-06-18 2018-10-12 Ambrx公司 新颖抗原结合多肽和其用途
HRP20141111T1 (hr) 2004-07-22 2015-01-02 Genentech, Inc. Sastav her2-protutijela
CA2580981C (en) 2004-09-22 2013-10-22 Kirin Beer Kabushiki Kaisha Stabilized human igg4 antibodies
ZA200704796B (en) 2004-12-07 2008-11-26 Genentech Inc Selecting patients for therapy with a HER inhibitor
GB0503546D0 (en) 2005-02-21 2005-03-30 Hellenic Pasteur Inst Antibody
KR101253576B1 (ko) 2005-02-23 2013-04-11 제넨테크, 인크. Ｈｅｒ 이량체화 억제제를 이용한 암 환자에서의 질환진행까지의 시간 또는 생존의 연장
EP1874820A4 (en) * 2005-04-20 2010-09-22 Amgen Fremont Inc HIGH AFFINE, COMPLETELY HUMAN MONOCLONAL ANTIBODY AGAINST INTERLEUKIN-8 AND EPITOPES FOR SUCH ANTIBODIES
EP1871424A2 (en) 2005-04-22 2008-01-02 Alza Corporation Immunoliposome composition for targeting to a her2 cell receptor
US8158590B2 (en) 2005-08-05 2012-04-17 Syntarga B.V. Triazole-containing releasable linkers, conjugates thereof, and methods of preparation
TW200732350A (en) 2005-10-21 2007-09-01 Amgen Inc Methods for generating monovalent IgG
US10155816B2 (en) 2005-11-28 2018-12-18 Genmab A/S Recombinant monovalent antibodies and methods for production thereof
US8940784B2 (en) 2006-02-02 2015-01-27 Syntarga B.V. Water-soluble CC-1065 analogs and their conjugates
WO2008007648A1 (fr) * 2006-07-10 2008-01-17 Institute For Antibodies Co., Ltd. Procédé de classification d'antigène, procédé d'identification d'antigène, procédé d'obtention d' un ensemble d'antigènes ou d'anticorps, procédés de construction d'un panel d'anticorps, anticorps et ens
JP5638804B2 (ja) 2006-08-04 2014-12-10 アストラゼネカ アクチボラグ ＥｒｂＢ２に対する抗体
ES2392630T3 (es) 2006-08-21 2012-12-12 F. Hoffmann-La Roche Ag Terapia antitumoral con anticuerpos anti-VEGF
WO2008031531A1 (en) 2006-09-15 2008-03-20 F. Hoffmann-La Roche Ag Tumor therapy with a combination of anti-her2 antibodies
AU2008205457A1 (en) 2007-01-18 2008-07-24 University Of Southern California Gene polymorphisms predictive for dual TKI therapy
WO2008097229A1 (en) 2007-02-09 2008-08-14 The Government Of The Usa As Represented By The Secretary Of The Dept. Of Health And Human Services Method for spectroscopic quantitation of her-2 in biological samples
EP2899541A1 (en) 2007-03-02 2015-07-29 Genentech, Inc. Predicting response to a HER dimerisation inhbitor based on low HER3 expression
EP2132227A1 (en) 2007-03-30 2009-12-16 F. Hoffmann-Roche AG Composition of labeled and non-labeled monoclonal antibodies
EP1980626A1 (en) 2007-04-13 2008-10-15 Het Nederlands Kanker Instituut Involvement of lipid kinase, and signal transduction pathway comprising said lipid kinase, in resistance to HER2-targeting therapy
ES2529790T3 (es) 2007-04-13 2015-02-25 Dana-Farber Cancer Institute, Inc. Métodos de tratamiento de cáncer resistente a agentes terapéuticos de ERBB
MX2009011228A (es) 2007-04-19 2009-11-02 Wellstat Biologics Corp Deteccion de niveles elevados de la proteina her-2/neu de celulas cancerosas circulantes no aisladas y tratamiento.
WO2008150485A2 (en) 2007-05-29 2008-12-11 Wyeth Erbb2 binding proteins and use thereof
JP6071165B2 (ja) 2007-05-31 2017-02-01 ゲンマブ エー／エス 安定なＩｇＧ４抗体
US8529901B2 (en) 2007-06-06 2013-09-10 Hoffmann-La Roche, Inc. Composition of a first non-labeled monoclonal antibody binding to a tumor antigen and a non-cross reactive second monoclonal antibody labeled with a NIR fluorescence label
CA2690334C (en) 2007-06-08 2017-02-14 Genentech, Inc. Gene expression markers of tumor resistance to her2 inhibitor treatment
DE102007031818A1 (de) 2007-07-07 2009-01-08 Daimler Ag Windschutzeinrichtung
ES2433379T3 (es) 2007-08-01 2013-12-10 Syntarga B.V. Análogos de CC-1065 sustituidos y sus conjugados
WO2009097006A2 (en) 2007-08-10 2009-08-06 Medarex, Inc. Hco32 and hco27 and related examples
US20110243927A1 (en) 2007-08-24 2011-10-06 University Health Network Methods of inhibiting tumor growth using beta 5 integrin antagonists
EP2190878A1 (en) 2007-09-06 2010-06-02 Genmab A/S Novel methods and antibodies for treating cancer
WO2009055074A2 (en) 2007-10-25 2009-04-30 Wyeth Erbb2 binding proteins and use thereof
GB0722704D0 (en) 2007-11-20 2007-12-27 Cadbury Schweppes Plc Confectionery product
WO2009068631A1 (en) 2007-11-27 2009-06-04 Ablynx N.V. Method for obtaining polypeptide constructs comprising two or more single domain antibodies
MX2010005683A (es) 2007-11-30 2010-06-11 Bristol Myers Squibb Co Conjugados de anticuerpos anti-rg-1.
TWI472339B (zh) 2008-01-30 2015-02-11 Genentech Inc 包含結合至ｈｅｒ２結構域ii之抗體及其酸性變異體的組合物
AU2009212442C1 (en) 2008-02-05 2014-07-17 Bristol-Myers Squibb Company Alpha 5 - beta 1 antibodies and their uses
US8394377B2 (en) 2008-02-21 2013-03-12 The Regents Of The University Of Colorado Methods for treating cancer using combination therapy
CN102076865B (zh) 2008-05-02 2016-03-16 西雅图基因公司 用于制造核心岩藻糖基化降低的抗体和抗体衍生物的方法和组合物
JP2010006705A (ja) * 2008-06-13 2010-01-14 Atlas Antibodies Ab Ｈｅｒ２サブセット
BRPI0812682A2 (pt) 2008-06-16 2010-06-22 Genentech Inc tratamento de cáncer de mama metastático
RU2547596C2 (ru) 2008-09-03 2015-04-10 Дженентек, Инк. Полиспецифические антитела
CN101721700A (zh) 2008-10-15 2010-06-09 哈药集团生物工程有限公司 一种抗人Her2抗体的冻干制剂
WO2010070117A1 (en) 2008-12-18 2010-06-24 Universite Libre De Bruxelles Treatment method by the administration of anti-her2 targeted active compounds to patients with early breast cancer and her2-negative primary tumor
CN101633695B (zh) 2009-04-15 2012-12-12 北京天广实生物技术股份有限公司 基于erbB2蛋白胞外区C-端功能表位特征设计抗erbB2功能抗体
US8446101B2 (en) 2009-07-20 2013-05-21 Gallen Ka Leung Tsui Control switch
JP6040148B2 (ja) * 2010-04-20 2016-12-07 ゲンマブ エー／エス ヘテロ二量体抗体Ｆｃ含有タンパク質およびその産生方法
NZ604007A (en) 2010-05-27 2015-03-27 Genmab As Monoclonal antibodies against her2 epitope
CA3051311A1 (en) 2010-05-27 2011-12-01 Genmab A/S Monoclonal antibodies against her2
AU2012245116A1 (en) 2011-04-20 2013-11-07 Genmab A/S Bispecific antibodies against HER2 and CD3
US20140170148A1 (en) * 2011-04-20 2014-06-19 Genmab A/S Bispecific antibodies against her2
WO2012143523A1 (en) * 2011-04-20 2012-10-26 Genmab A/S Bispecifc antibodies against her2

Also Published As

Publication number Publication date
WO2011147982A2 (en) 2011-12-01
NZ604007A (en) 2015-03-27
US20180022816A1 (en) 2018-01-25
JP2017046694A (ja) 2017-03-09
CN103153339A (zh) 2013-06-12
US20130171148A1 (en) 2013-07-04
CN103153339B (zh) 2021-05-04
US9714294B2 (en) 2017-07-25
CA2800769C (en) 2021-11-02
CA2800769A1 (en) 2011-12-01
WO2011147982A3 (en) 2012-03-15
JP6438442B2 (ja) 2018-12-12
JP2013534809A (ja) 2013-09-09
IL245274B (en) 2019-08-29
IL245274A0 (en) 2016-06-30
JP6082344B2 (ja) 2017-02-15
EP2575880B1 (en) 2019-01-16
US10793640B2 (en) 2020-10-06
US20210122830A1 (en) 2021-04-29
EP2575880A2 (en) 2013-04-10

Similar Documents

Publication Publication Date Title
IL245274B (en) Monoclonal antibodies against the 2her epitope
IL245275A0 (en) Monoclonal antibodies against 2her
DK3904391T3 (en) Monoclonal antibodies against c-met
ES3065861T3 (en) Interleukin-31 monoclonal antibody
IL220404A (en) Antiseptic antibodies
IL222359A0 (en) Monoclonal antibodies against her2 antigens, and uses therefor
PT2536764T (pt) Anticorpos humanizados anti-cd28
ZA201206835B (en) New humanized anti-cd20 monoclonal antibory
ZA201202227B (en) Monoclonal antibodies
HRP20141257T1 (en) Antibodies against her2 truncated variant ctf-611
EP2707392A4 (en) MONOCLONAL ANTIBODY FOR ACETYLAMANTADINE
IL267022A (en) Monoclonal antibodies against 2her
PT2545077T (pt) Anticorpos monoclonais contra c-met